Test Price
2,800 AED✅ Home Collection Available
RDH11 Gene Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
✅ 99.9% Diagnostic Sensitivity via ISO 9001:2015‑certified NGS processing.
🚚 Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (8 AM – 11 PM) with ISO‑certified transport.
📞 Clinical Guidance: Telephonic post‑test result interpretation by DHA‑licensed Clinical Geneticist.
💳 Insurance: Direct billing verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This targeted Next‑Generation Sequencing (NGS) test screens the entire coding region of the RDH11 gene, revealing pathogenic variants linked to autosomal recessive retinal dystrophy, juvenile cataracts, and syndromic short stature. Designed for ophthalmologists, pediatricians, and clinical geneticists, the assay delivers a definitive molecular diagnosis in 3–4 weeks.
| Feature | Our Test – RDH11 NGS | Closest Alternative – Single‑Gene Sanger |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) – full gene coverage | Sanger sequencing – selected exons only |
| Diagnostic Yield | >99% of known pathogenic variants detected | ~80% (misses deep intronic & regulatory variants) |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Report | Clinically annotated with ACMG classification, ICD‑10‑CM codes, LOINC mapping | Basic variant listing |
Physician Insight & Safety Protocols
“While this NGS test offers exceptional analytical sensitivity, a positive result must be correlated with complete ophthalmologic and systemic phenotyping. A negative report does not exclude all genetic etiologies—other retinal dystrophy genes or copy‑number variations may still be involved. I always recommend a detailed pre‑test genetic counselling session to align expectations.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Safety Advisory
Do not discontinue any prescribed medication without explicit instruction from your treating physician. This genetic test does not assess drug efficacy or guide acute therapy.
Exclusion Criteria & Emergency Red Flags
- Patients without clinical suspicion for RDH11‑related syndromic retinal dystrophy (isolated myopia or adult‑onset cataract alone are insufficient indications).
- Unwillingness or inability to participate in pre‑test genetic counselling and provide a three‑generation family history.
- Active febrile illness or recent blood transfusion (<2 weeks) may delay collection but do not invalidate the test.
- Seek emergency care if you experience sudden profound vision loss, acute eye pain, severe headache, or photophobia—these are not related to the test but require immediate ophthalmic evaluation.
Patient FAQ & Clinical Guidance
1. What is the RDH11 gene test and who should consider it?
A: This NGS test analyses the RDH11 gene to confirm inherited retinal dystrophy, juvenile cataracts and syndromic short stature in children or adults with suggestive clinical signs. It is most appropriate for individuals with early‑onset retinal degeneration, congenital/juvenile cataracts, and growth delay—especially when there is a family history of these features. A positive result enables precise genetic counselling, informs prognosis, and guides surveillance for extra‑ocular manifestations.
2. How accurate is NGS testing for RDH11‑related retinal dystrophy?
A: The test achieves >99.9% analytical sensitivity for single nucleotide variants and small insertions/deletions within the RDH11 coding region, using ISO‑validated sequencing chemistry. Clinical accuracy depends on comprehensive variant interpretation following ACMG guidelines; all reports are reviewed by a DHA‑licensed molecular geneticist to minimise false‑positive calls.
3. Will my insurance cover the cost of this genetic test in the UAE?
A: Many UAE insurers cover medically necessary single‑gene testing when pre‑authorised by a consultant ophthalmologist or clinical geneticist; we offer direct billing verification via WhatsApp before sample collection. Please message +971 54 548 8731 with your insurance card and referral letter for instant confirmation.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
All patient data is handled in strict adherence to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow the provisions of Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our laboratory is ISO 9001:2015 certified and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | RDH11 Gene Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral Whole Blood – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily 8 AM – 11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full coding region coverage |
| ICD‑10‑CM Code | H35.5 (Hereditary retinal dystrophy) |
| LOINC Code | 48000-4 (Gene targeted mutation analysis) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians